PureTech Health PLC PRTC Names Robert Lyne as Chief Portfolio Officer
27 Setembro 2023 - 3:05AM
RNS Non-Regulatory
TIDMPRTC
PureTech Health PLC
27 September 2023
27 September 2023
PureTech Health plc
PureTech Announces the Appointment of Robert Lyne as Chief
Portfolio Officer
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company dedicated to
changing the lives of patients with devastating diseases , today
announced the appointment of Robert Lyne as Chief Portfolio
Officer. Robert brings a decade of experience in international life
science deals and portfolio management, along with governance and
executive team leadership experience. Robert is expected to join
PureTech by early January 2024.
"We are excited to welcome Rob to our management team and
pleased to add a dedicated presence representing our senior
leadership team in the UK as we work to deliver impactful new
treatments for patients," said Daphne Zohar, Founder and Chief
Executive Officer of PureTech. "His extensive legal, operational
and UK listed IP commercialization experience is complementary to
PureTech's own hub-and-spoke business model. We are looking forward
to working together closely as we realize the full potential of
both our Wholly Owned Programs and Founded Entity stakes and
royalties."
Mr. Lyne joins PureTech from Arix Bioscience plc, a
transatlantic venture capital company focused on investing in
innovative biotechnology companies, where he served as General
Counsel and Chief Operating Officer before being appointed Chief
Executive Officer in April 2021. He began his career as a lawyer at
international law firm Bird & Bird LLP in London before moving
to Touchstone Innovations, a London listed biotech and technology
investor, which was acquired in 2017. He has worked on over 80
venture capital financings in Europe and North America as well as
multiple trade exits and IPOs. As an experienced UK plc executive,
Mr. Lyne has broad experience formulating and implementing
corporate strategy. Mr. Lyne has a BA from the University of Oxford
and an LLB from Oxford Brookes University.
"I am delighted to be joining the management team at PureTech
during such an exciting time in the Company's growth," said Mr.
Lyne. "As pioneers of the hub-and-spoke model in the biotechnology
sector, PureTech's approach is aligned with my own experience and
ambitions. They are highly innovative in their approach to both
science and business, which has led to the team delivering an
impressive track record of developing new therapies with
transformational potential. I look forward to working with the
skilled team at PureTech and its outstanding network of advisors to
further drive the Company forward."
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to giving life to new classes of medicine to change the lives of
patients with devastating diseases. The Company has created a broad
and deep pipeline through its experienced research and development
team and its extensive network of scientists, clinicians and
industry leaders that is being advanced both internally and through
its Founded Entities. PureTech's R&D engine has resulted in the
development of 27 therapeutics and therapeutic candidates,
including two (Plenity(R) and EndeavorRx(R)) that have received
both US FDA clearance and European marketing authorization and a
third (KarXT) that is expected to be filed soon for FDA approval. A
number of these programs are being advanced by PureTech or its
Founded Entities in various indications and stages of clinical
development, including registration enabling studies. All of the
underlying programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and
then advanced by the PureTech team through key validation
points.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including without limitation those
statements that relate to our expectations around our product
candidates and approach towards addressing major diseases, and our
future prospects, developments, and strategies. The forward-looking
statements are based on current expectations and are subject to
known and unknown risks, uncertainties and other important factors
that could cause actual results, performance and achievements to
differ materially from current expectations, including, but not
limited to, those risks, uncertainties and other important factors
described under the caption "Risk Factors" in our Annual Report on
Form 20-F for the year ended December 31, 2022 filed with the SEC
and in our other regulatory filings. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the Company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law and regulatory requirements, we disclaim any
obligation to update or revise these forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact:
PureTech
Public Relations
publicrelations@puretechhealth.com
Investor Relations
IR@puretechhealth.com
EU Media
Ben Atwell, Rob Winder
+44 (0) 20 3727 1000
ben.atwell@FTIconsulting.com
U.S. Media
Nichole Sarkis
+1 774 278 8273
nichole@tenbridgecommunications.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAPPUCWBUPWPUQ
(END) Dow Jones Newswires
September 27, 2023 02:05 ET (06:05 GMT)
Puretech Health (LSE:PRTC)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Puretech Health (LSE:PRTC)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024